
The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.
The AUA 2018 take-home messages in outcomes also covered topics such as environmental exposures and bladder cancer and onabotulinumtoxinA (Botox) treatment for patients with overactive bladder.
The AUA 2018 take-home messages in outcomes also covered topics such as environmental exposures and bladder cancer and onabotulinumtoxinA (Botox) treatment for patients with overactive bladder. The take-homes were presented by Willie Underwood, III, MD, MPH, MSci, of Roswell Park Comprehensive Cancer Center, Buffalo, NY.